CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

by Vandana Singh, Benzinga Editor
January 30, 2023 10:17 AM | 2 min read |
Loading...
Loading...
  • CureVac N.V. CVAC announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK plc GSK. The newly reported data focus on older adult age groups.
  • COVID-19 Program
  • Newly reported immunogenicity data from CV0501 in older adults (age ≥65) are based on the fully recruited dose groups of 12, 25 and 50µg, consisting of 10 subjects per dose. 
  • On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against BA.1 of 13.3.
  • While CV0501 encodes the Omicron BA.1 variant, a Phase 2 study, expected to start in 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants.
  • Related: Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation.
  • Seasonal Flu Program
  • A single dose of Flu-SV-mRNA (dose level undisclosed) was assessed for safety and reactogenicity in older adults (age 60-80) and was observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. 
  • Adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA in older adults were approximately 2.3 times those elicited by the licensed vaccine comparator. 
  • In the same age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.
  • The vaccine candidate for future clinical development is expected to target all four flu virus strains currently recommended by the WHO for influenza vaccines. 
  • A Phase 1/2 study for multivalent vaccine candidates is expected to start around mid-2023.
  • Price Action: CVAC shares are up 8.82% at $12.40 on the last check Monday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechLarge CapNewsHealth CareMoversGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!